US Equities Analysis

LLY — Lilly (Eli)

LLY Price Chart FCF Yield Dividend Yield Price / Earnings Price / Book EV / EBITDA EV / NOPAT Consensus EPS Broker Sentiment EBITDA Margin EBIT Margin ROIC & ROE Capital Turnover Capex & WC / Sales Net Debt / Equity Price and 100d MA Relative to Index Relative to MSCI


1. Industry Fundamentals

1.1 Cyclicality

The company operates in a cyclical industry sensitive to macroeconomic conditions. Revenue and earnings tend to correlate with broader economic cycles, with periods of expansion driving growth and contractions creating headwinds. Current market capitalisation: 1013.35B.

1.2 Competition

The industry is moderately competitive with established players and meaningful barriers to entry. Beta of 0.52 suggests moderate market sensitivity. Competitive advantages stem from brand, scale, or regulatory moats.

1.3 Technology

Key technology drivers include digital transformation, operational efficiency, automation. Companies that invest in R&D and adopt new technologies tend to gain market share. The pace of technological change creates both opportunities for innovation and risks of disruption.


2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 49.39%
Profit Margins 34.99%
Return on Equity 107.46%
Return on Assets 20.74%
Free Float 0.89B
Dividend Yield 0.57%
Short Int % Utilisation 1.1%

2.2 Growth

Metric Value
Revenue Growth 55.5%
Free Cash Flow 9.16B
EBITDA 29.03 (Ratio)
Enterprise Value 1051.44B
EV/Revenue 14.55
EV/EBITDA 29.03

Revenue growth of 55.5% places the company in a high-growth category.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.) 38.83%
Risk / Std Dev (Ann.) 32.45%
Sharpe Ratio (rf=4.5%) 1.06
Beta 0.52

2.5 Valuation

Metric Value
P/E (Forward) 25.54
Price/Book 31.71
EV/Revenue 14.55
EV/EBITDA 29.03
Enterprise Value / NOPAT 35.84
FCF Yield (%) 0.93%
Price / Earnings 39.37
Price / Book 31.71
Enterprise Value / EBITDA 28.31

Forward P/E of 26x is at a moderate premium, reflecting growth expectations.

2.6 Return Outlook

The stock’s historical risk-return profile shows an annualised expected return of 38.8% with annualised volatility of 32.5%, yielding a Sharpe ratio of 1.06 (rf=4.5%). The risk-adjusted return is attractive relative to the risk-free rate. With a beta of 0.5, the stock is less volatile than the market, offering relative downside protection.


us-equitystockequityllyhealth-carepharmaceuticalsnasdaq